Kali Inc. (KALY)

[BuyLoweSellHi]

New York, NY -- January 24, 2019 -- InvestorsHub NewsWire -- Kali, Inc. (USOTC: KALY) has proven to be a new hot cannabis stock over the past two months and an upcoming trigger could rocket the current $0.01 PPS up 1000% to a $0.10 PPS.

The company entered the cannabis sector recently acquiring a patented cannabis extraction technology. The technology has been licensed by Puration, Inc. (USOTC: PURA) for the production of CBT infused water sold into the sports nutrition market. Together, KALY and PURA singed a deal to make a private labeled CBD infused water for Generex Biotechnology (OTCQB: GNBT). KALY also introduced its own CBD infused candies under the brand name Hemp4mula. KALY’s greatest and yet unrecognized value is derived from the company’s medical research surrounding the extracts from the patented extraction process.

The acquisition of the patented extraction process and the corresponding contract announcements saw the PPS rocket out of the sub-penny range on trading volume that put it regularly in the top 25 most actively traded stocks on the OTCMarkets. The jump in price and volume resulted in OTCMarkets flagging the stock for potential promotion concerns. However, since the OTCMarkets flag was posted, the company has updated its financial filings bringing them current with OTCMarkets reporting standards for a current information filer. The company has also launched a new website consistent with its new cannabis business plan. Its’ likely that OTCMarkets is reviewing KALY’s updated filings and reviewing the increase in PPS and volume in reaction to the new business plan and acquired assets and that the reviews will lead to a removal of the currently posted flag for potential promotion concerns.

The removal of the flag could be seen as a validation of the company’s legitimate new cannabis business plan and assets and could in turn be a trigger for another PPS run. When considering KALY compared to a company such as Cannabis Science, (USOTC: CBIS) with its negligible revenue, massive losses and delinquent filings, but a $100 million market cap, it is not unreasonable to think KALY’s PPS could run to $0.10 in response to a clean bill of health, patented technology, revenue, and current filings.